Delving into the Latest Updates on NM-6606 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

ACT500, NM 6606, NM-6606

+ [1]

Target

RXRA

Mechanism

RXRA agonists(Retinoid X receptor alpha agonists)

Therapeutic Areas

Digestive System Disorders

Active Indication

Nonalcoholic Steatohepatitis

Inactive Indication-

Originator Organization

Tengji (Xiamen) Biomedical Technology Co., Ltd.

Active Organization

Xiamen Amoytop Biotech Co. Ltd.Tengji (Xiamen) Biomedical Technology Co., Ltd.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

This is a single-center, randomized, double-blind, placebo-controlled Phase I clinical study, divided into two parts. The first part is a single-dose escalation study (Part1,SAD study phase), and the second part is a multiple-dose escalation study (Part2,MAD study phase). It's aimed to evaluate the safety, tolerability, and pharmacokinetics (PK) of ACT500 in healthy adult participants, and to explore possible metabolites and biomarkers of ACT500.

Start Date01 Jan 2025

Sponsor / Collaborator

Xiamen Amoytop Biotech Co. Ltd.

[+1]

CTR20244213 / Not yet recruitingPhase 1

评价ACT500（曾用名NM6606）单、多次剂量递增在中国健康成年受试者中安全性、耐受性和药代动力学特征的单中心、随机、双盲、安慰剂对照的Ⅰ期临床研究

[Translation] A single-center, randomized, double-blind, placebo-controlled Phase I clinical study to evaluate the safety, tolerability and pharmacokinetic characteristics of single and multiple ascending doses of ACT500 (formerly known as NM6606) in healthy Chinese adult subjects

1.评估ACT500在健康成年受试者中单次和多次口服给药的安全性和耐受性； 2.评估ACT500及其代谢物在健康成年受试者中单次和多次口服给药的药代动力学（PK）特征； 3.探索ACT500在健康成年受试者中单次和多次口服给药的代谢产物和生物标志物。

[Translation]

1. Evaluate the safety and tolerability of ACT500 after single and multiple oral administration in healthy adult subjects; 2. Evaluate the pharmacokinetic (PK) characteristics of ACT500 and its metabolites after single and multiple oral administration in healthy adult subjects; 3. Explore the metabolites and biomarkers of ACT500 after single and multiple oral administration in healthy adult subjects.

Start Date-

Sponsor / Collaborator

Tengji (Xiamen) Biomedical Technology Co., Ltd.

100 Clinical Results associated with NM-6606

Login to view more data

100 Translational Medicine associated with NM-6606

Login to view more data

100 Patents (Medical) associated with NM-6606

Login to view more data

100 Deals associated with NM-6606

Login to view more data